drugset / Trial / NCT00687271

A Study of MK-6213 Co-Administered With Atorvastatin in Participants With Hypercholesterolemia (MK-6213-006)

NCT00687271

Phase 2 Completed 334 enrolled Merck Sharp & Dohme LLC
RandomizedFactorialDouble-blindTreatment

Summary

The purpose of this study is to test the safety and effectiveness of MK-6213 as compared to MK-6213/Atorvastatin in participants 18 to 75 years) with high cholesterol.

Timeline

Start
2008-06-14
Primary completion
2009-01-08
Completion
2009-01-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 20 mg Oral
Subject MK-6213 Unknown 160 mg Oral

Indications